Zanubrutinib for treating relapsed or refractory mantle cell lymphoma | TA1081 | | |
One-piece closed bags for colostomies: late-stage assessment | HTE29 | | |
Pulsed-field ablation for atrial fibrillation | IPG806 | | |
Mirikizumab for previously treated moderately to severely active Crohn's disease | TA1080 | | |
Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment | HTE28 | | |
Dapagliflozin for treating chronic kidney disease | TA1075 | | |
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal) | TA1076 | | |
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA1077 | | |
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) | TA1078 | | |
Sparsentan for treating primary IgA nephropathy | TA1074 | | |
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies | TA1073 | | |
Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation | IPG805 | | |
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1071 | | |
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA1072 | | |
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | HTE27 | | |
Intrapartum care | NG235 | | |
Spesolimab for treating generalised pustular psoriasis flares | TA1070 | | |
Targeted muscle reinnervation for managing limb amputation pain | IPG804 | | |
Caesarean birth | NG192 | | |
Linzagolix for treating symptoms of endometriosis | TA1067 | | |
Efgartigimod for treating antibody-positive generalised myasthenia gravis | TA1069 | | |
Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease | IPG803 | | |
Somapacitan for treating growth hormone deficiency in people 3 to 17 years | TA1066 | | |
Headaches in over 12s: diagnosis and management | CG150 | | |
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) | TA1068 | | |
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA1065 | | |
Abortion care | NG140 | | |
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA1064 | | |
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment | TA1063 | | |
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor | TA1062 | | |
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1060 | | |
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma | TA1059 | | |
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment | HTE25 | | |
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal) | TA1061 | | |
Drug-eluting stents for treating coronary artery disease: late-stage assessment | HTE26 | | |
Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment | HTE24 | | |
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | TA878 | | |
COVID-19 rapid guideline: managing COVID-19 | NG191 | | |
Suspected cancer: recognition and referral | NG12 | | |
Slide sheets for moving or repositioning a person: late-stage assessment | HTE23 | | |
Falls: assessment and prevention in older people and in people 50 and over at higher risk | NG249 | | |
Falls | QS86 | | |
Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over | HST33 | | |
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) | TA1058 | | |
Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour | IPG800 | | |
Robot-assisted surgery for soft tissue procedures: early value assessment | HTE21 | | |
Robot-assisted surgery for orthopaedic procedures: early value assessment | HTE22 | | |
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA1055 | | |
Molnupiravir for treating COVID-19 | TA1056 | | |
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis | TA1057 | | |